Denise Neves Gameiro, Author at Labiotech.eu

About

Journalist intern. Studied Bioengineering in Porto and was a lab rat in Sweden. Enjoying Berlin and the company of Labiotech’s resident plants.

Articles by Denise Neves Gameiro

cellectis ucart leukemia cancer gmp manufacturing ucart19 ucart123 allogeneic universal 2015 financial results

News and Trends 16 Mar 2016

How Good was 2015 for the French Universal CAR-T Biotech?

Cellectis (France) has now released its financial results for 2015. What happened and what the prospects for 2016 and long-term? It was a really packed year for Cellectis, the French Champion for universal, off-the-shelf CAR-T treatments. The Biopharma saw significant advances in multiple fronts, from clinical development to financing. The first therapy initially developed by […]

March 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

deinove deinococci biorefinery green chemistry arbiom biomass wood pretreatment lignin optafuel biomethodes bioskog

News and Trends 15 Mar 2016

French SynBio Biotech to ferment wood for Carbon-free Future

Deinove (Montpelier) and Arbiom (Evry) are two Biotechs from France which have now partnered to transform wood residues into added-value chemicals – a step closer to the ideal Bioeconomy. Deinove is one of our favourite Green Chemistry and SynBio Biotechs, developing micro-factories with their library of Deinococcus. Its projects range from using tobacco plants to making carotenoids, also with […]

March 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

nanobiotix private placement €21M nanoxray sarcoma liver head neck prostate cancer nbtxr3 nanomedicine radiotherapy localized

News and Trends 15 Mar 2016

French Nanomedicine Biotech Gets €21M to Kill Cancer with ‘Beam Rays’

Nanobiotix (France) has had a successful private placement in, raising €21.3M to advance the clinical development of its localised radiotherapy for Cancer. Located in Paris’ superbiocluster, Nanobiotix wants to change the way cancer is treated – but in a different way from most Biotech strategies. It is developing NanoXRay, a paradigm-shifting nanotechnology for localised radiotherapy. Nanobiotix has […]

March 15, 2016 - 2 minutesmins - By Denise Neves Gameiro

cambridge epigenix true methyl oxsb seq epigenome sequencing 5mc 5hmc gv sequoia geoff smith

News and Trends 14 Mar 2016

British Startup Raises Millions to Become the Illumina for Epigenetics

Cambridge Epigenetix (UK) wants to unlock the power of the Epigenome and become what Illumina is for NGS. And now, it has gotten the €18.9M and a new CEO needed to achieve this. Cambrige Epigenetix is a Biotech developing epigenetic tools, and was initially founded by Cambridge Enterprise (an incubator of the University of Cambridge) and […]

March 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

zika mosquito oxitcec fda swarm florida trial genetic engineering infectious disease

News and Trends 14 Mar 2016

Florida to release Genetically Engineered Mosquitoes to stop Zika Virus

Oxitec (UK) is on track to be allowed to trial their self-limiting, genetically engineered mosquitoes in the US – and stop the spread of Dengue and Zika. As a spin-off from Oxford University, Oxitec specialises in using genetic engineering to control insect pest populations with the ‘Sterile Insect Technique’. This is an interesting alternative to pesticides […]

March 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

genfit nash fatty liver disease elfibranor PPAR phase III resolve it

News and Trends 11 Mar 2016

Genfit Has Enroled its First Patient in a NASH Phase III Trial

Genfit (France) has enroled their first patient in the highly anticipated phase III trial (RESOLVE-IT) for NASH, a fatty-liver disease currently without any approved treatment. This is good news for Genfit, which managed to kickstart a phase III trial for their lead candidate, Elafibranor, just one year after the read-out of the phase IIb results. There […]

March 11, 2016 - 2 minutesmins - By Denise Neves Gameiro

nature cancer reviews lumd leiden isa pharmaceuticals immuno oncology immunotherapies checkpointblocking chemotherapy immunosupression

News and Trends 11 Mar 2016

Reviewing Immuno-Oncology: What works and what doesn’t

Researchers from Leiden University Medical Center (LUMC) and ISA Pharmaceuticals (Netherlands) have authored an extensive review of what is working in immuno-oncology – and what hasn’t. The review was accepted in the well-known journal Nature Reviews Cancer and it covers the findings of 250 peer-reviewed papers about immunotherapies. Immuno-oncology is radically changing the way cancer is being […]

March 11, 2016 - 4 minutesmins - By Denise Neves Gameiro

capella biosciences medicxi ventures advent life sciences osage university partners mabs monoclonal antibodies oncology autoimmune target biology

News and Trends 10 Mar 2016

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

Capella Biosciences (UK) is a life sciences start-up specializing in antibodies. It has just raised an additional €14.3M in a Series A round to develop their antibody pipeline to clinical stages. Capella started out in 2014 and based in London, defining its mission as developing therapeutic monoclonal antibodies for unmet medical needs. Back then, it received […]

March 10, 2016 - 2 minutesmins - By Denise Neves Gameiro

aprea ovarian cancer p53 protein apr 246 karolinska versant ventures 5am ventures healthcap

News and Trends 10 Mar 2016

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

Aprea (Sweden) is not a well-know Biotech (yet), but has succeeded in raising €46M from big investors in the US and Europe. Why? For its First-in-class potential for a famous cancer target… Aprea started in 2003 as a spin-off from cancer research at Karolinska Institutet, in its technology-transfer program. This Biotech has a promising candidate […]

March 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

prime priority medicines ema european medicine agency breakthrough therapy fast track biotech

News and Trends 9 Mar 2016

EMA Launches its own Fast Track for Breakthrough Therapies

The European Medicine Agency (EMA) is launching a priority scheme for therapies addressing unmet medical needs, similar to the FDA’s fast track. The key objective is to help European patients get earlier access to therapies that could be lifesaving, and this could have significant impact on the European Biotech industry. This new PRIME fast-track will include a […]

March 9, 2016 - 2 minutesmins - By Denise Neves Gameiro

boehringer ingelheim abbvie psoriasis interleukin23 bi655066 bi655066 Crohns asthma psoriatic arthritis

News and Trends 9 Mar 2016

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Boehringer Ingelheim (Germany) has entered a new collaboration with AbbVie (US) to develop two new candidates for immune diseases, including psoriasis and Crohn’s disease. Therapies for immune diseases continue to attract Pharma’s attention (and money). This time, two of 25 leading Big Pharma worldwide, AbbVie and Boehringer Ingelheim, have partnered to develop 2 different immunological candidates. […]

March 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

spark therapeutics genable gene therapy blindness pigmentosa rhonova

News and Trends 8 Mar 2016

Irish Gene Therapy for Blindness is Acquired by US Leader in the Field

Spark Therapeutics (US) has paid over €13.5M for Genable Technologies (Ireland) and its gene therapy for a degenerative eye disease which progresses to blindness. Spark Therapeutics is one of the players in the re-emerging field of Gene Therapy (which is already establishing records like the most expensive drug). It focuses on debilitating genetic diseases, like inherited […]

March 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Denise Neves Gameiro

About

Articles by Denise Neves Gameiro

How Good was 2015 for the French Universal CAR-T Biotech?

French SynBio Biotech to ferment wood for Carbon-free Future

French Nanomedicine Biotech Gets €21M to Kill Cancer with ‘Beam Rays’

British Startup Raises Millions to Become the Illumina for Epigenetics

Florida to release Genetically Engineered Mosquitoes to stop Zika Virus

Genfit Has Enroled its First Patient in a NASH Phase III Trial

Reviewing Immuno-Oncology: What works and what doesn’t

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

EMA Launches its own Fast Track for Breakthrough Therapies

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Irish Gene Therapy for Blindness is Acquired by US Leader in the Field

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Denise Neves Gameiro

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!